Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
Investigational medicinal products submitted over the course of 3 years and authorized at the Clinical Trials Office of the Italian Medicines Agency as part of a request for authorization of clinical trials were scrutinized to identify those encompassing nanomedicines. The quality assessment reports...
Saved in:
Main Authors: | Diego Alejandro Dri (Author), Elisa Gaucci (Author), Ilaria Torrieri (Author), Maria Carafa (Author), Carlotta Marianecci (Author), Donatella Gramaglia (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
by: Diego Alejandro Dri, et al.
Published: (2021) -
Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
by: Diego Alejandro Dri, et al.
Published: (2021) -
Smart Nanovesicles for Drug Targeting and Delivery
by: Carlotta Marianecci, et al.
Published: (2019) -
Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials
by: Zahra Eskandari, et al.
Published: (2020) -
Polycaprolactone Nanoparticles as Promising Candidates for Nanocarriers in Novel Nanomedicines
by: Sylwia Łukasiewicz, et al.
Published: (2021)